View clinical trials related to Infectious Disease.
Filter by:The research aims to determine the impact of a syndromic mutiplex PCR assay (FilmArray) on the management of patients hospitalized in ICU for severe respiratory disease. During the SARS-CoV-2 outbreak, the diagnosis of pneumonia has become considerably more complex as the biological, radiological and clinical criteria of covid-19 interfere with the standard criteria for the diagnosis of severe respiratory diseases. Moreover, patients with COVID-19 are at higher risk of developing other associated infections and thus, patients have therefore often been treated with antibiotics, adequately or not, due to difficulty to quickly identify the etiology of their symptoms with conventional methods. In order to improve their treatment, both diagnostic and therapeutic, we set up a new syndromic molecular test in our laboratories to accelerate and improve the pneumonia management and antibiotic stewardship. This research will include 100 to 150 adult patients hospitalized in ICU during the first half of 2020. It will take place within the Nancy University Hospital and the Reims University Hospital, France.
Consensual antibiotic protocols have been developed and validated locally by infectious disease specialists, internists and emergency physicians, in order to encourage their compliance. A preliminary study was conducted from June 2015 to February 2016, including 622 patients admitted to the emergency department for infectious syndrome such as / - Pneumoniae - Urinary tract infection - Cellulitis - Meningitis - Malaria - Febrile neutropenia - Febrile acute diarrhea - Fever back to the tropics - Angina - sexually transmitted infection This prospective study will observe and analyze the adherence of prescribers to these protocols. With description of patients who benefited or not the antibiotic protocol, according to a syndromic approach and analysis of the causes of non-adherence to the protocols. In order to limit the length of stay and reduce the cost of hospitalization..
1. National, large-scale, standardized, standardized, real-world research; 2. Prospective, single - arm open, non - interventional, registration, multi - center clinical study; 3. in the use of cefuroxime axetil dispersible tablets in the hospital, according to the principle of voluntary selection of 200; 4. registration of the use of cefuroxime axetil dispersion tablets patients; 5. Target sample size of 100,000 cases; 6. Exemption from informed consent for ethical review applications; 7. Antibiotic drug safety re-evaluation of large data.
1. Primary study endpoint Security Effectiveness 2. Secondary study endpoint Extensive use of population characteristics Clinical drug characteristics appropriate crowd characteristics Adverse reactions susceptible population characteristics Reveal rare, new, unanticipated and long-term adverse drug reactions bacterial resistance Explore the advantages of teicoplanin in combination with other antimicrobial agents Explore the opportunistic use of teicoplanin for injection